Efficacy and mechanism of action of harmine derivative H-2-104 against Echinococcus granulosus infection in mice.

IF 2.3 2区 农林科学 Q1 VETERINARY SCIENCES
Huijing Gao, Qinwei Xu, Jiang Zhu, Kadierya Kuerban, Bei Chen, Jun Zhao, Kalibixiati Aimulajiang, Liang Teng
{"title":"Efficacy and mechanism of action of harmine derivative H-2-104 against Echinococcus granulosus infection in mice.","authors":"Huijing Gao, Qinwei Xu, Jiang Zhu, Kadierya Kuerban, Bei Chen, Jun Zhao, Kalibixiati Aimulajiang, Liang Teng","doi":"10.1186/s12917-025-04642-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cystic echinococcosis (CE) is a chronic zoonotic parasitic disease caused by the parasite Echinococcus granulosus (E. granulosus). Currently, pharmacologic treatments are limited to albendazole and mebendazole; however, these treatments are associated with significant side effects and limited therapeutic efficacy, highlighting the urgent need for the development of new drugs. Harmine (HM) has been reported to exhibit potent antiparasitic effects, although it is also accompanied by notable neurotoxicity. H-2-104, a derivative of HM obtained through structural modification of its parent nucleus, represents a promising candidate for further investigation. This study aims to assess the in vivo and in vitro efficacy of H-2-104 against E. granulosus and to elucidate the mechanism of action of H-2-104 against CE from a metabolomics perspective.</p><p><strong>Methods: </strong>In vitro pharmacodynamics experiments were conducted to assess the inhibitory activity of H-2-104 against E. granulosus protoscoleces (PSCs). Following this, a mouse model of E. granulosus infection was established to explore the inhibitory effects against E. granulosus of H-2-104 at low, medium, and high concentrations. Additionally, non-targeted metabolomic approaches were utilized to analyze the serum and liver samples from mice in the control group, model group, and H-2-104 treatment group with the aim of identifying relevant biomarkers and crucial metabolic pathways involved in the response to H-2-104 treatment.</p><p><strong>Results: </strong>The in vitro results demonstrated that H-2-104 exhibited significantly superior inhibitory activity against PSCs compared to harmine and albendazole. Morphological observations revealed marked alterations in the ultrastructural characteristics of PSCs treated with H-2-104. In vivo pharmacodynamic studies showed that H-2-104 at a dosage of 100 mg/kg exhibited the highest cyst inhibition rate, which was (73.60 ± 4.71)%. Metabolomics analysis revealed that 64 serum metabolites were significantly altered, primarily involving metabolic pathways such as necroptosis, linoleic acid metabolism, and phenylalanine metabolism. Additionally, 81 liver metabolites were identified with significant differences, mainly involving metabolic pathways like fructose and mannose metabolism, and glycerophospholipid metabolism.</p><p><strong>Conclusions: </strong>H-2-104 exhibits significant activity both in vitro and in vivo, suggesting its potential as a promising new drug for the treatment of CE. The anti-CE effects of H-2-104 may be attributed to its regulation of multiple biological pathways, including cell apoptosis, amino acid metabolism, and glucose metabolism.</p>","PeriodicalId":9041,"journal":{"name":"BMC Veterinary Research","volume":"21 1","pages":"174"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912776/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Veterinary Research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1186/s12917-025-04642-x","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cystic echinococcosis (CE) is a chronic zoonotic parasitic disease caused by the parasite Echinococcus granulosus (E. granulosus). Currently, pharmacologic treatments are limited to albendazole and mebendazole; however, these treatments are associated with significant side effects and limited therapeutic efficacy, highlighting the urgent need for the development of new drugs. Harmine (HM) has been reported to exhibit potent antiparasitic effects, although it is also accompanied by notable neurotoxicity. H-2-104, a derivative of HM obtained through structural modification of its parent nucleus, represents a promising candidate for further investigation. This study aims to assess the in vivo and in vitro efficacy of H-2-104 against E. granulosus and to elucidate the mechanism of action of H-2-104 against CE from a metabolomics perspective.

Methods: In vitro pharmacodynamics experiments were conducted to assess the inhibitory activity of H-2-104 against E. granulosus protoscoleces (PSCs). Following this, a mouse model of E. granulosus infection was established to explore the inhibitory effects against E. granulosus of H-2-104 at low, medium, and high concentrations. Additionally, non-targeted metabolomic approaches were utilized to analyze the serum and liver samples from mice in the control group, model group, and H-2-104 treatment group with the aim of identifying relevant biomarkers and crucial metabolic pathways involved in the response to H-2-104 treatment.

Results: The in vitro results demonstrated that H-2-104 exhibited significantly superior inhibitory activity against PSCs compared to harmine and albendazole. Morphological observations revealed marked alterations in the ultrastructural characteristics of PSCs treated with H-2-104. In vivo pharmacodynamic studies showed that H-2-104 at a dosage of 100 mg/kg exhibited the highest cyst inhibition rate, which was (73.60 ± 4.71)%. Metabolomics analysis revealed that 64 serum metabolites were significantly altered, primarily involving metabolic pathways such as necroptosis, linoleic acid metabolism, and phenylalanine metabolism. Additionally, 81 liver metabolites were identified with significant differences, mainly involving metabolic pathways like fructose and mannose metabolism, and glycerophospholipid metabolism.

Conclusions: H-2-104 exhibits significant activity both in vitro and in vivo, suggesting its potential as a promising new drug for the treatment of CE. The anti-CE effects of H-2-104 may be attributed to its regulation of multiple biological pathways, including cell apoptosis, amino acid metabolism, and glucose metabolism.

鼠尾草碱衍生物H-2-104抗小鼠细粒棘球蚴感染的疗效及作用机制。
背景:囊性棘球蚴病是由细粒棘球绦虫引起的一种慢性人畜共患寄生虫病。目前,药物治疗仅限于阿苯达唑和甲苯达唑;然而,这些治疗方法副作用大,治疗效果有限,迫切需要开发新的药物。据报道,毒碱(HM)具有有效的抗寄生虫作用,但也伴有显著的神经毒性。H-2-104是HM的衍生物,通过对其母核进行结构修饰得到,是一个有希望进一步研究的候选者。本研究旨在评价H-2-104对颗粒棘球蚴的体内外药效,并从代谢组学角度阐明H-2-104对CE的作用机制。方法:采用体外药效学实验评价H-2-104对颗粒棘球蚴原头节(PSCs)的抑制作用。在此基础上,建立小鼠颗粒棘球蚴感染模型,探讨低、中、高浓度H-2-104对颗粒棘球蚴的抑制作用。此外,利用非靶向代谢组学方法分析对照组、模型组和H-2-104治疗组小鼠的血清和肝脏样本,目的是确定与H-2-104治疗反应相关的生物标志物和关键代谢途径。结果:体外实验结果表明,H-2-104对PSCs的抑制活性明显优于鼠胺和阿苯达唑。形态学观察显示,H-2-104处理后的PSCs超微结构特征发生了显著变化。体内药效学研究表明,100 mg/kg剂量的H-2-104对囊肿的抑制率最高,为(73.60±4.71)%。代谢组学分析显示,64种血清代谢物显著改变,主要涉及代谢途径,如坏死性坏死、亚油酸代谢和苯丙氨酸代谢。此外,鉴定出81种肝脏代谢物存在显著差异,主要涉及果糖和甘露糖代谢、甘油磷脂代谢等代谢途径。结论:H-2-104在体外和体内均表现出显著的活性,提示其有望成为治疗CE的新药。H-2-104的抗ce作用可能与其调控多种生物学途径有关,包括细胞凋亡、氨基酸代谢和葡萄糖代谢。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Veterinary Research
BMC Veterinary Research VETERINARY SCIENCES-
CiteScore
4.80
自引率
3.80%
发文量
420
审稿时长
3-6 weeks
期刊介绍: BMC Veterinary Research is an open access, peer-reviewed journal that considers articles on all aspects of veterinary science and medicine, including the epidemiology, diagnosis, prevention and treatment of medical conditions of domestic, companion, farm and wild animals, as well as the biomedical processes that underlie their health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信